{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T18:25:43Z","timestamp":1780943143159,"version":"3.54.1"},"reference-count":50,"publisher":"Elsevier BV","issue":"30","license":[{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1016\/j.vaccine.2013.04.071","type":"journal-article","created":{"date-parts":[[2013,5,9]],"date-time":"2013-05-09T08:45:57Z","timestamp":1368089157000},"page":"3039-3045","source":"Crossref","is-referenced-by-count":54,"title":["A novel tetrameric gp3501\u2013470 as a potential Epstein\u2013Barr virus vaccine"],"prefix":"10.1016","volume":"31","author":[{"given":"Xinle","family":"Cui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhouhong","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goutam","family":"Sen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gouri","family":"Chattopadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah H.","family":"Fuller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James T.","family":"Fuller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dustin M.","family":"Snapper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew L.","family":"Snow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James J.","family":"Mond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clifford M.","family":"Snapper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"August (2)","key":"10.1016\/j.vaccine.2013.04.071_bib0005","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jaci.2005.05.038","article-title":"EBV the prototypical human tumor virus\u2014just how bad is it?","volume":"116","author":"Thorley-Lawson","year":"2005","journal-title":"J Allergy Clin Immunol"},{"issue":"November (23)","key":"10.1016\/j.vaccine.2013.04.071_bib0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S1462399404008440","article-title":"Infectious mononucleosis and Epstein\u2013Barr virus","volume":"6","author":"Vetsika","year":"2004","journal-title":"Expert Rev Mol Med"},{"issue":"July (2)","key":"10.1016\/j.vaccine.2013.04.071_bib0015","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0092-8674(87)90216-9","article-title":"Epstein\u2013Barr virus gp350\/220 binding to the B lymphocyte C3d receptor mediates adsorption, capping, and endocytosis","volume":"50","author":"Tanner","year":"1987","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.vaccine.2013.04.071_bib0020","doi-asserted-by":"crossref","first-page":"4452","DOI":"10.1128\/JVI.62.12.4452-4464.1988","article-title":"Soluble gp350\/220 and deletion mutant glycoproteins block Epstein\u2013Barr virus adsorption to lymphocytes","volume":"62","author":"Tanner","year":"1988","journal-title":"J Virol"},{"issue":"August (2)","key":"10.1016\/j.vaccine.2013.04.071_bib0025","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1128\/JVI.43.2.730-736.1982","article-title":"Identification and isolation of the main component (gp350\u2013gp220) of Epstein\u2013Barr virus responsible for generating neutralizing antibodies in vivo","volume":"43","author":"Thorley-Lawson","year":"1982","journal-title":"J Virol"},{"issue":"February (7\/8)","key":"10.1016\/j.vaccine.2013.04.071_bib0030","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0264-410X(98)00248-5","article-title":"Expression of Epstein\u2013Barr virus gp350 as a single chain glycoprotein for an EBV subunit vaccine","volume":"17","author":"Jackman","year":"1999","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2013.04.071_bib0035","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/jmv.1890130310","article-title":"Comparative immunogenicity studies on Epstein\u2013Barr virus membrane antigen (MA) gp340 with novel adjuvants in mice, rabbits, and cotton-top tamarins","volume":"13","author":"Morgan","year":"1984","journal-title":"J Med Virol"},{"issue":"September (1)","key":"10.1016\/j.vaccine.2013.04.071_bib0040","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1002\/jmv.1890290114","article-title":"Validation of a first-generation Epstein\u2013Barr virus vaccine preparation suitable for human use","volume":"29","author":"Morgan","year":"1989","journal-title":"J Med Virol"},{"issue":"February (Pt 2)","key":"10.1016\/j.vaccine.2013.04.071_bib0045","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1099\/0022-1317-73-2-449","article-title":"Protective immunization against Epstein\u2013Barr virus-induced disease in cottontop tamarins using the virus envelope glycoprotein gp340 produced from a bovine papillomavirus expression vector","volume":"73","author":"Finerty","year":"1992","journal-title":"J Gen Virol"},{"issue":"October (13)","key":"10.1016\/j.vaccine.2013.04.071_bib0050","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1016\/0264-410X(94)90240-2","article-title":"Immunization of cottontop tamarins and rabbits with a candidate vaccine against the Epstein\u2013Barr virus based on the major viral envelope glycoprotein gp340 and alum","volume":"12","author":"Finerty","year":"1994","journal-title":"Vaccine"},{"issue":"August (4)","key":"10.1016\/j.vaccine.2013.04.071_bib0055","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/(SICI)1096-9071(199808)55:4<255::AID-JMV1>3.0.CO;2-#","article-title":"Immunization of common marmosets with Epstein\u2013Barr virus (EBV) envelope glycoprotein gp340: effect on viral shedding following EBV challenge","volume":"55","author":"Cox","year":"1998","journal-title":"J Med Virol"},{"issue":"November (3)","key":"10.1016\/j.vaccine.2013.04.071_bib0060","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/(SICI)1096-9071(199611)50:3<263::AID-JMV9>3.0.CO;2-7","article-title":"Immunisation of common marmosets with vaccinia virus expressing Epstein\u2013Barr virus (EBV) gp340 and challenge with EBV","volume":"50","author":"Mackett","year":"1996","journal-title":"J Med Virol"},{"issue":"March (Pt 3)","key":"10.1016\/j.vaccine.2013.04.071_bib0065","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1099\/0022-1317-74-3-501","article-title":"Replication-defective recombinant adenovirus expressing the Epstein\u2013Barr virus (EBV) envelope glycoprotein gp340\/220 induces protective immunity against EBV-induced lymphomas in the cottontop tamarin","volume":"74","author":"Ragot","year":"1993","journal-title":"J Gen Virol"},{"issue":"June (2)","key":"10.1016\/j.vaccine.2013.04.071_bib0070","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/jmv.1890250209","article-title":"Recombinant vaccinia virus expressing Epstein\u2013Barr virus glycoprotein gp340 protects cottontop tamarins against EB virus-induced malignant lymphomas","volume":"25","author":"Morgan","year":"1988","journal-title":"J Med Virol"},{"key":"10.1016\/j.vaccine.2013.04.071_bib0075","first-page":"171","article-title":"First EBV vaccine trial in humans using recombinant vaccinia virus expressing the major membrane antigen","volume":"84","author":"Gu","year":"1995","journal-title":"Dev Biol Stand"},{"issue":"December (12)","key":"10.1016\/j.vaccine.2013.04.071_bib0080","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1086\/523813","article-title":"Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein\u2013Barr virus vaccine in healthy young adults","volume":"196","author":"Sokal","year":"2007","journal-title":"J Infect Dis"},{"issue":"June (24)","key":"10.1016\/j.vaccine.2013.04.071_bib0085","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1016\/j.vaccine.2007.04.008","article-title":"Phase I\/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein\u2013Barr virus vaccine in healthy adults","volume":"25","author":"Moutschen","year":"2007","journal-title":"Vaccine"},{"issue":"October (8)","key":"10.1016\/j.vaccine.2013.04.071_bib0090","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1097\/TP.0b013e3181b9d918","article-title":"A phase I trial of Epstein\u2013Barr virus gp350 vaccine for children with chronic kidney disease awaiting transplantation","volume":"88","author":"Rees","year":"2009","journal-title":"Transplantation"},{"issue":"February (2)","key":"10.1016\/j.vaccine.2013.04.071_bib0095","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1002\/eji.200425749","article-title":"High epitope density in a single protein molecule significantly enhances antigenicity as well as immunogenicity: a novel strategy for modern vaccine development and a preliminary investigation about B cell discrimination of monomeric proteins","volume":"35","author":"Liu","year":"2005","journal-title":"Eur J Immunol"},{"issue":"June (26)","key":"10.1016\/j.vaccine.2013.04.071_bib0100","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1016\/j.vaccine.2008.03.078","article-title":"Adjuvant potential of aggregate-forming polyglutamine domains","volume":"26","author":"Ilyinskii","year":"2008","journal-title":"Vaccine"},{"issue":"October (10)","key":"10.1016\/j.vaccine.2013.04.071_bib0105","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1089\/jir.2010.0086","article-title":"On the role of aggregates in the immunogenicity of recombinant human interferon beta in patients with multiple sclerosis","volume":"30","author":"van Beers","year":"2010","journal-title":"J Interferon Cytokine Res"},{"issue":"November (11)","key":"10.1016\/j.vaccine.2013.04.071_bib0110","doi-asserted-by":"crossref","first-page":"3305","DOI":"10.1002\/1521-4141(200211)32:11<3305::AID-IMMU3305>3.0.CO;2-J","article-title":"Regulation of IgG antibody responses by epitope density and CD21-mediated costimulation","volume":"32","author":"Jegerlehner","year":"2002","journal-title":"Eur J Immunol"},{"issue":"3","key":"10.1016\/j.vaccine.2013.04.071_bib0115","doi-asserted-by":"crossref","first-page":"E501","DOI":"10.1208\/aapsj080359","article-title":"Effects of protein aggregates: an immunologic perspective","volume":"8","author":"Rosenberg","year":"2006","journal-title":"AAPS J"},{"issue":"October (13)","key":"10.1016\/j.vaccine.2013.04.071_bib0120","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/0264-410X(94)90237-2","article-title":"Enhanced immunogenicity of protein-dextran conjugates: I. Rapid stimulation of enhanced antibody responses to poorly immunogenic molecules","volume":"12","author":"Lees","year":"1994","journal-title":"Vaccine"},{"issue":"January (5247)","key":"10.1016\/j.vaccine.2013.04.071_bib0125","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1126\/science.271.5247.348","article-title":"C3d of complement as a molecular adjuvant: bridging innate and acquired immunity","volume":"271","author":"Dempsey","year":"1996","journal-title":"Science"},{"issue":"February (2)","key":"10.1016\/j.vaccine.2013.04.071_bib0130","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1046\/j.1537-2995.1995.35295125736.x","article-title":"Construction of bacteriophage expressing mouse monoclonal Fab fragments directed against the human MN glycophorin blood group antigens","volume":"35","author":"Czerwinski","year":"1995","journal-title":"Transfusion (Paris)"},{"issue":"January (4890)","key":"10.1016\/j.vaccine.2013.04.071_bib0135","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1126\/science.2911757","article-title":"Evidence that the leucine zipper is a coiled coil","volume":"243","author":"O'Shea","year":"1989","journal-title":"Science"},{"issue":"February (3)","key":"10.1016\/j.vaccine.2013.04.071_bib0140","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/0092-8674(89)90240-7","article-title":"Identification of an epitope in the major envelope protein of Epstein\u2013Barr virus that mediates viral binding to the B lymphocyte EBV receptor (CR2)","volume":"56","author":"Nemerow","year":"1989","journal-title":"Cell"},{"issue":"January (1)","key":"10.1016\/j.vaccine.2013.04.071_bib0145","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/0042-6822(84)90102-8","article-title":"Early events in the infection of human B lymphocytes by Epstein\u2013Barr virus: the internalization process","volume":"132","author":"Nemerow","year":"1984","journal-title":"Virology"},{"issue":"August (3)","key":"10.1016\/j.vaccine.2013.04.071_bib0150","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.4049\/jimmunol.167.3.1490","article-title":"Kinetic analysis of the interactions of complement receptor 2 (CR2, CD21) with its ligands C3d, iC3b, and the EBV glycoprotein gp350\/220","volume":"167","author":"Sarrias","year":"2001","journal-title":"J Immunol"},{"issue":"July (2)","key":"10.1016\/j.vaccine.2013.04.071_bib0155","doi-asserted-by":"crossref","first-page":"717","DOI":"10.4049\/jimmunol.149.2.717","article-title":"Use of human universally antigenic tetanus toxin T cell epitopes as carriers for human vaccination","volume":"149","author":"Valmori","year":"1992","journal-title":"J Immunol"},{"issue":"January (1)","key":"10.1016\/j.vaccine.2013.04.071_bib0160","doi-asserted-by":"crossref","first-page":"532","DOI":"10.4049\/jimmunol.172.1.532","article-title":"Differential regulation of IgG anti-capsular polysaccharide and antiprotein responses to intact Streptococcus pneumoniae in the presence of cognate CD4+ T cell help","volume":"172","author":"Khan","year":"2004","journal-title":"J Immunol"},{"issue":"November\u2013December (1\/2)","key":"10.1016\/j.vaccine.2013.04.071_bib0165","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.cellimm.2005.01.010","article-title":"The critical DNA flanking sequences of a CpG oligodeoxynucleotide, but not the 6 base CpG motif, can be replaced with RNA without quantitative or qualitative changes in Toll-like receptor 9-mediated activity","volume":"232","author":"Sen","year":"2004","journal-title":"Cell Immunol"},{"issue":"15","key":"10.1016\/j.vaccine.2013.04.071_bib0170","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/0264-410X(95)00069-D","article-title":"Gene gun-based nucleic acid immunization: elicitation of humoral and cytotoxic T lymphocyte responses following epidermal delivery of nanogram quantities of DNA","volume":"13","author":"Pertmer","year":"1995","journal-title":"Vaccine"},{"issue":"December (12)","key":"10.1016\/j.vaccine.2013.04.071_bib0175","doi-asserted-by":"crossref","first-page":"8258","DOI":"10.4049\/jimmunol.181.12.8258","article-title":"A novel ICOS-independent, but CD28- and SAP-dependent, pathway of T cell-dependent, polysaccharide-specific humoral immunity in response to intact Streptococcus pneumoniae versus pneumococcal conjugate vaccine","volume":"181","author":"Chen","year":"2008","journal-title":"J Immunol"},{"issue":"August (3)","key":"10.1016\/j.vaccine.2013.04.071_bib0180","doi-asserted-by":"crossref","first-page":"923","DOI":"10.4049\/jimmunol.143.3.923","article-title":"Analysis of epitope expression and the functional repertoire of recombinant complement receptor 2 (CR2\/CD21) in mouse and human cells","volume":"143","author":"Carel","year":"1989","journal-title":"J Immunol"},{"issue":"December (12)","key":"10.1016\/j.vaccine.2013.04.071_bib0185","doi-asserted-by":"crossref","first-page":"6375","DOI":"10.1128\/IAI.67.12.6375-6384.1999","article-title":"Cognate stimulatory B-cell-T-cell interactions are critical for T-cell help recruited by glycoconjugate vaccines","volume":"67","author":"Guttormsen","year":"1999","journal-title":"Infect Immun"},{"issue":"May (5)","key":"10.1016\/j.vaccine.2013.04.071_bib0190","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1073\/pnas.77.5.2979","article-title":"Monoclonal antibody against a 250,000-dalton glycoprotein of Epstein\u2013Barr virus identifies a membrane antigen and a neutralizing antigen","volume":"77","author":"Hoffman","year":"1980","journal-title":"Proc Natl Acad Sci USA"},{"issue":"September (9)","key":"10.1016\/j.vaccine.2013.04.071_bib0195","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1586\/erv.09.82","article-title":"Prospects for developing an effective particle-mediated DNA vaccine against influenza","volume":"8","author":"Yager","year":"2009","journal-title":"Expert Rev Vaccines"},{"issue":"November (7\/8)","key":"10.1016\/j.vaccine.2013.04.071_bib0200","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/S0264-410X(00)00302-9","article-title":"Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine","volume":"19","author":"Roy","year":"2000","journal-title":"Vaccine"},{"issue":"October (4)","key":"10.1016\/j.vaccine.2013.04.071_bib0205","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.4049\/jimmunol.135.4.2319","article-title":"Carrier-induced epitopic suppression, a major issue for future synthetic vaccines","volume":"135","author":"Schutze","year":"1985","journal-title":"J Immunol"},{"issue":"September (5)","key":"10.1016\/j.vaccine.2013.04.071_bib0210","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.4049\/jimmunol.145.5.1343","article-title":"The in vivo elimination of CD4+ T cells prevents the induction but not the expression of carrier-induced epitopic suppression","volume":"145","author":"Leclerc","year":"1990","journal-title":"J Immunol"},{"issue":"April (8)","key":"10.1016\/j.vaccine.2013.04.071_bib0215","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.4049\/jimmunol.142.8.2635","article-title":"Carrier-induced epitopic suppression is initiated through clonal dominance","volume":"142","author":"Schutze","year":"1989","journal-title":"J Immunol"},{"issue":"December (6)","key":"10.1016\/j.vaccine.2013.04.071_bib0220","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1084\/jem.174.6.1299","article-title":"Determination of the structural basis for selective binding of Epstein\u2013Barr virus to human complement receptor type 2","volume":"174","author":"Martin","year":"1991","journal-title":"J Exp Med"},{"issue":"November (11)","key":"10.1016\/j.vaccine.2013.04.071_bib0225","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/nri2868","article-title":"Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns","volume":"10","author":"Bachmann","year":"2010","journal-title":"Nat Rev Immunol"},{"issue":"May (5)","key":"10.1016\/j.vaccine.2013.04.071_bib0230","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1128\/IAI.69.5.3031-3040.2001","article-title":"Increased immunogenicity and induction of class switching by conjugation of complement C3d to pneumococcal serotype 14 capsular polysaccharide","volume":"69","author":"Test","year":"2001","journal-title":"Infect Immun"},{"issue":"August (2)","key":"10.1016\/j.vaccine.2013.04.071_bib0235","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/77802","article-title":"C3d enhancement of antibodies to hemagglutinin accelerates protection against influenza virus challenge","volume":"1","author":"Ross","year":"2000","journal-title":"Nat Immunol"},{"key":"10.1016\/j.vaccine.2013.04.071_bib0240","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1146\/annurev.iy.13.040195.001015","article-title":"The CD19\/CR2\/TAPA-1 complex of B lymphocytes: linking natural to acquired immunity","volume":"13","author":"Fearon","year":"1995","journal-title":"Annu Rev Immunol"},{"issue":"February (1)","key":"10.1016\/j.vaccine.2013.04.071_bib0245","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.smim.2007.12.001","article-title":"Follicular dendritic cell networks of primary follicles and germinal centers: phenotype and function","volume":"20","author":"Allen","year":"2008","journal-title":"Semin Immunol"},{"issue":"3","key":"10.1016\/j.vaccine.2013.04.071_bib0250","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1002\/1521-4141(200003)30:3<969::AID-IMMU969>3.0.CO;2-A","article-title":"sustained activation of human B cells by anti-immunoglobulin conjugated to the EBV glycoprotein gp350","volume":"30","author":"Goeckeritz","year":"2000","journal-title":"Eur J Immunol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X13005409?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X13005409?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T16:13:06Z","timestamp":1688227986000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X13005409"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":50,"journal-issue":{"issue":"30","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["S0264410X13005409"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2013.04.071","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,6]]}}}